Navigation Links
Tamoxifen Helps Treat Bipolar Disorder
Date:9/12/2007

Discovery may lead to new drug to treat manic phase of the illness, study says

WEDNESDAY, Sept. 12 (HealthDay News) -- The breast cancer drug tamoxifen helps control the manic phase of bipolar disorder, and works faster than many standard medications used to treat the chronic mental illness, a new study has found.

"One of the problems with existing treatments for bipolar disorder is they seem to have this long period before they start to work," explained Dr. Husseini K. Manji, senior study author and director of the U.S. National Institute of Mental Health's mood and anxiety disorders program.

Current treatments sometimes take weeks to become effective, Manji said. "And that obviously creates a huge problem," he said. When patients are in the manic phase, particularly, not getting relief fast enough from medication may mean they need to be hospitalized, he noted.

For the study, Manji and his colleagues gave eight patients experiencing a manic episode tamoxifen, while another eight received a placebo; no one knew which drug they were getting. After three weeks, 63 percent of those on tamoxifen had reduced symptoms of mania, compared to just 13 percent of those on a placebo. The tamoxifen group responded by the fifth day of treatment.

The study results are published online in the September issue of Bipolar Disorders.

Manji and his colleagues decided to study tamoxifen because they knew that standard medications used to treat mania are known to lower the activity of an enzyme called protein kinase C, or PKC, that regulates activities in brain cells. This enzyme is believed to become overactive when bipolar disorder patients experience a manic episode.

Tamoxifen also blocks PKC, but does it more directly than some bipolar drugs, according to the researchers.

Manji and his team made the discovery after years of searching for the correct cellular target to treat bipolar disorder, which affects almost 6 million American adults. Symptoms can be disabling, including profound mood swings, from depression to the manic phase, during which people can become overly excited and energetic but also irritable, before they plunge into depression again.

For the study, Manji said, "we started with 20 milligrams [of tamoxifen] a day. It was increased each day, usually up to 100 milligrams a day. "Literally at day five we saw this significant anti-mania effect," he said, adding that with standard medications it would have taken three weeks to see results.

"If we had something that would nip mania in the bud, it might save people from being hospitalized and getting sedating agents," Manji said.

A new bipolar drug would not be tamoxifen itself, he said, but rather another medicine that mimics what tamoxifen does in the brain. The development of such a drug would probably take at least five years before it could be approved for marketing, he said.

Dr. Gary S. Sachs, director of the bipolar clinic and research program at Massachusetts General Hospital and associate professor of psychiatry at Harvard Medical School, called the results "encouraging."

Sachs said he was aware of other research with similar findings. "I wouldn't say this study proves that tamoxifen works faster than standard [treatment,]" he said, since a head-to-head comparison was not done. But, while not definitive, "the study has important findings," he said.

More information

To learn more about bipolar disorder, visit the U.S. National Institute of Mental Health.



SOURCES: Husseini K. Manji, M.D., director, mood and anxiety disorders program, National Institute of Mental Health, Bethesda, Md.; Gary Sachs, M.D., director, bipolar clinic and research program, Massachusetts General Hospital, and associate professor, psychiatry, Harvard Medical School, Boston; September 2007 Bipolar Disorders, online


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Letrozole Beats Tamoxifen in Breast Cancer Therapy
2. Tamoxifen does not adversely affect the brain
3. Tamoxifen reduces breast cancer risk
4. Tamoxifen reduces breast cancer risk
5. Aromatase Inhibitors drug Femara after Tamoxifen therapy protects from breast cancer recurrence
6. Tamoxifen Ineffective In Presence Of Genetic Variation in Breast Cancer
7. New Drug More Effective than Tamoxifen in Preventing Breast Cancer Relapse
8. Raloxifene Better Than Tamoxifen For Breast Cancer
9. Aromatase Inhibitors Better Than Tamoxifen For Treating Receptor-Positive Early Breast Cancer
10. Study Identifies Mechanism Which May Help Tamoxifen Work Better
11. Tamoxifen Discontinuation Rates Surprisingly High
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to ... since it streamlines the reporting process and provides a familiar interface that does ...
(Date:4/28/2017)... York, NY (PRWEB) , ... April 28, 2017 ... ... Medical Laboratory to expanded distribution of the GlycoMark test throughout the Northeast U.S. ... recent hyperglycemia in patients with diabetes. The GlycoMark test provides a clinically proven ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic Back Surgery and ... revolutionary endoscopic practice under Dr. Datta. Patel is a Board Certified Anesthesiologist, with ... revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is unlike traditional back ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection ... improve drug safety and minimize the cost of development. In this webinar, sponsored ... using cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... pilot study of ActiGraph’s CentrePoint Data Hub in a sample of ... of clinical-grade wearable activity and sleep monitoring solutions for the global scientific community. ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... , April 18, 2017 Cogentix Medical, Inc. ... providing the Urology, Uro/Gyn and Gynecology markets with innovative ... first quarter ended March 31, 2017 after the market ... The Company will host a conference call and webcast ... Tuesday, May 2, 2017 at 4:30 p.m. Eastern Time ...
(Date:4/18/2017)... 18, 2017 Research and Markets has announced ... report to their offering. ... global arthroscopy devices market to grow at a CAGR of 6.35% ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:4/18/2017)... SAN DIEGO and BLOOMINGTON, ... Pharmaceuticals, Inc. (NASDAQ: IMMY ) ("Imprimis"), ... d/b/a Precision Lens ("Precision Lens"), today announced the ... Under the agreement, Precision Lens will deploy a ... into select geographies in the U.S., primarily focused ...
Breaking Medicine Technology: